Supriya Lifescience Ltd

Supriya Lifescience Financial Results

Supriya Lifescience reported a ₹209.12 Crore annual net profit for FY26. The board also recommended a final dividend of ₹1 per equity share.

Value

₹209.1 Cr

Supriya Lifescience Board Meeting Date

Supriya Lifescience scheduled a board meeting on May 27, 2026. Directors will consider audited financial results and recommend a potential dividend for fiscal year 2026.

Supriya Lifescience Debt & Borrowing

Supriya Lifescience Ltd informed exchanges that it does not qualify as a 'Large Corporate' per SEBI criteria for FY 2026-27. The company reported nil outstanding borrowings and an A+ credit rating from India Ratings. This disclosure confirms compliance with debt-market borrowing framework requirements.

Supriya Lifescience Regulatory Approval

Supriya Lifescience Ltd successfully completed a USFDA inspection at its Lote manufacturing facility. The inspection, conducted in February 2026, concluded with one minor observation and the receipt of an Establishment Inspection Report (EIR) indicating Voluntary Action Indicated (VAI) status. This confirms the facility's compliance with current Good Manufacturing Practice (cGMP) standards.

Supriya Lifescience Annual General Meeting

Supriya Lifescience Limited announced the passing of three special resolutions via postal ballot with requisite majority. Shareholders approved the appointments of Mr. Manish Panchal and Mr. Kothandaraman Hari, and the re-appointment of Dr. Neelam Arora, as Non-Executive Independent Directors for five-year terms.

Execution

5 years